Sheena Demelo
Bristol-Myers Squibb (United States)(US)Dana-Farber Cancer Institute(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Brain Metastases and Treatment, Immunotherapy and Immune Responses, Nanoplatforms for cancer theranostics
Most-Cited Works
- → Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain(2018)1,297 cited
- → Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.(2017)126 cited
- → Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).(2017)6 cited
- → Abstract LB-055: Overall survival and safety experience from an expanded access program (EAP) of nivolumab (NIVO) for patients with advanced melanoma (MEL) who progressed after prior ipilimumab (IPI) treatment(2017)1 cited